Top 5 Most Viewed Diabetes Content in 2024

The most viewed diabetes articles of 2024 highlighted important advances and challenges in diabetes care, from breakthrough treatments. FDA approval Toward continued discussion regarding treatment approaches. These top articles and interviews cover pediatric metabolic health, misconceptions about glucagon-like peptide 1 (GLP-1) receptor agonists, affordability barrierand its influence Interruption of treatment.

Here are the top 5 most-watched diabetes movies of 2024: Check out the rest of our diabetes news. here.

5. Dr. Robert Lustig on Pediatric Metabolic Health: “Sugar is Children's Alcohol”

in Value-Based Medicine Institute^® At this year's event, Robert Lustig, MD, endocrinologist and professor emeritus of pediatrics at the University of California, San Francisco, will move from a focus on obesity to addressing the metabolic dysfunction that affects 93% of Americans, including children. advocated the transformation of In this interview, he explained how sugar causes type 2 diabetes and fatty liver disease in children, and compared sugar's effect on the liver to that of alcohol. Lustig also called for a shift in medical indicators from BMI to measurements such as waist circumference and fasting insulin to address the root causes of metabolic dysfunction.

Check out the interview.

4. The CCS report reveals misconceptions about people living with diabetes. Call for increased engagement and education

A survey of more than 1,500 people with diabetes revealed significant misconceptions, including 57% of respondents believing that GLP-1 weight loss drugs alone can take care of their health. Arti Masturzo, MD, MBA, chief medical officer at CCS, said these drugs should be part of a comprehensive care strategy that includes personalized education, coaching and medical device support. The survey also revealed gaps in patient engagement. Many patients want more support during doctor visits and more early education at the time of diagnosis.

Please read the article.

3. Most insured adults still have to pay at least part of the cost of GLP-1 drugs

Top diabetes content focused on pediatric metabolic health, new diabetes management options, and more. |Image credit: Sherry Young – Stock.adobe.com

The KFF Health Tracking Poll found that affordability remains a major challenge for GLP-1 users, with more than half of insured adults still paying out-of-pocket. The survey highlighted the diverse uses of these drugs, with 39% using them for chronic conditions such as diabetes and heart disease, and 38% for weight loss. Although public awareness of GLP-1 is rapidly increasing, barriers such as high price and limited Medicare coverage remain, especially for weight loss purposes.

Please read the article.

2. What happens to diabetics when semaglutide is discontinued? Dr. Ian Kneeland explains

In this January interview, Ian Kneeland, MD, of Harrington University Hospital Harrington Heart and Vascular Institute, discussed the risks for diabetic patients facing semaglutide deficiency. These include losing blood sugar control, experiencing uncontrolled diabetes symptoms, and facing adverse events. Professor Nieland also highlighted the challenges in switching drugs, as alternative options may not have the cardiovascular or renal benefits of GLP-1 receptor agonists. Inappropriate reintroduction of semaglutide at previously stable doses can also cause serious side effects, highlighting the need for patient education and careful management.

Check out the interview.

1. FDA approves first over-the-counter continuous glucose monitor

In March, the FDA approved the Dexcom Stelo glucose biosensor system, the first continuous glucose monitor (CGM) available over the counter. Designed for adults who don't require insulin therapy, the system helps track blood sugar levels through a smartphone app, and each wearable sensor lasts 15 days. This milestone expands access to CGM, allowing individuals with and without diabetes to monitor blood sugar levels without the need for a prescription.

Please read the article.